Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

OBJECTIVES: To evaluate the cost-effectiveness of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in basal–bolus regimens for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk based on the DEVOTE CV outcomes trial. METHODS: A microsimulation model,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Appl Health Econ Health Policy
Main Authors: Pollock, Richard F., Valentine, William J., Marso, Steven P., Andersen, Andreas, Gundgaard, Jens, Hallén, Nino, Tutkunkardas, Deniz, Magnuson, Elizabeth A., Buse, John B.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2019
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6748892/
https://ncbi.nlm.nih.gov/pubmed/31264138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40258-019-00494-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados